Osavampator
As of the edition of 20 October 2026, Osavampator is a small molecule: in active development; acts on GRIA1, GRIA2 and GRIA3 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 9, 1 stopped early
- Disease areas
- Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 5 | 0 | 5 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Neurocrine | Lead sponsor of trials | 2015 to now |
| Takeda | Lead sponsor of trials | 2018 to now |